Evidence map›Paper›PMID 35894637›Full record

ArticleBlood advances2022

Gender and early-career faculty disparities in hematology and oncology board review lecture series.

Sebawe Syaj, Leen Al-Kraimeen, Marah Akhdar, Hassan Abushukair, Razan Mohty, Samer Al Hadidi

Abstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sebawe SyajFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-8605-5306
Leen Al-KraimeenFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-0875-4443
Marah AkhdarFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0003-2947-0818
Hassan AbushukairFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-0068-5201
Razan MohtyDivision of Hematology/Oncology and Blood and Bone Marrow Transplantation and Cellular Therapy, Mayo Clinic, Jacksonville, FL.ORCID 0000-0002-0189-8233
Samer Al HadidiMyeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Participation of women and early-career faculty in hematology and medical oncology board review lecture series has not been studied previously. We aimed to evaluate gender and early-career faculty disparities in hematology and medical oncology board review lecture series. Speakers at major hematology and/or oncology board review lecture series meetings in the United States were analyzed in this cross-sectional study during a 5-year period from the years 2017 through 2021. Data about the lecture topic, field, speaker's gender, years of experience, and the frequency at which the lecture was given by the speaker were collected. Of 386 speakers participating, 315 (81.6%) were ABIM (American Board of Internal Medicine)-certified. A total of 1,224 board review lectures were given in the studied period, of which 1,016 (83%) were given by an ABIM-certified speaker. Women constituted 37.7% of all speakers, with less than 50% representation in five out of six courses. Lectures discussing malignant hematology topics had the lowest proportion of women presenters (24.8%), followed by solid tumors (38.9%) and benign hematology lectures (44.1%). Faculty with more than 15 years since initial certification presented more than 50% of lectures. The median time from initial hematology or medical oncology certification to lecture presentation was 12.5 years and 14 years, respectively. A positive trend in the participation of women was found at all board review conferences across the studied period. Our data suggest that women and early-career faculty participation in hematology and oncology board review series is inadequate.

Indexed as

HematologyCertificationCross-Sectional StudiesFacultyFemaleHumansMedical OncologyUnited States

Identifiers

PMID35894637
PMCPMC9791299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.